Cardiac effects of sulfonylurea-related hypoglycemia

Diabetes Care

Volumn 40, Issue 5, 2017, Pages 663-670

  Middleton, Timothy L ^a,b   Wong, Jencia ^a,b   Molyneaux, Lynda ^a   Brooks, Belinda A ^a,b   Yue, Dennis K ^a,b   Twigg, Stephen M ^a,b   Wu, Ted ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; SULFONYLUREA; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; INSULIN; SULFONYLUREA DERIVATIVE;

ADULT; AGED; AMBULATORY ELECTROCARDIOGRAPHY; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ECTOPIA CORDIS; FEMALE; GLUCOSE BLOOD LEVEL; HEART ARRHYTHMIA; HEART RATE; HEART REPOLARIZATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; QT PROLONGATION; QTC INTERVAL; BLOOD; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; HEART; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

AGED; ARRHYTHMIAS, CARDIAC; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; HEART; HEART RATE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; SULFONYLUREA COMPOUNDS;

EID: 85019373987     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-1972     Document Type: Conference Paper

References (40)

1. Gerstein HC, Miller ME, Byington RP, et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559
2. Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572
3. Duckworth W, Abraira C, Moritz T, et al.; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139
4. Zoungas S, Patel A, Chalmers J, et al.; ADVANCE Collaborative Group. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010;363:1410-1418
5. Hay LC, Wilmshurst EG, Fulcher G. Unrecognized hypo- and hyperglycemia in well-controlled patients with type 2 diabetes mellitus: the results of continuous glucose monitoring. Diabetes Technol Ther 2003;5:19-26
6. Gehlaut RR, Dogbey GY, Schwartz FL, Marling CR, Shubrook JH. Hypoglycemia in type 2 diabetes-more common than you think: a continuous glucose monitoring study. J Diabetes Sci Technol 2015;9:999-1005
7. Frier BM. Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications. Nat Rev Endocrinol 2014;10:711-722
8. Stahn A, Pistrosch F, Ganz X, et al. Relationship between hypoglycemic episodes and ventricular arrhythmias in patients with type 2 diabetes and cardiovascular diseases: silent hypoglycemias and silent arrhythmias. Diabetes Care 2014;37:516-520
9. Chow E, Bernjak A, Williams S, et al. Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk. Diabetes 2014;63:1738-1747
10. Tsujimoto T, Yamamoto-Honda R, Kajio H, et al. Vital signs, QT prolongation, and newly diagnosed cardiovascular disease during severe hypoglycemia in type 1 and type 2 diabetic patients. Diabetes Care 2014;37:217-225
11. Lee AS, Brooks BA, Simmons L, et al. Hypoglycaemia and QT interval prolongation: detection by simultaneous Holter and continuous glucose monitoring. Diabetes Res Clin Pract 2016;113:211-214
12. Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V. Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care 2003;26:1485-1489
13. Abdelmoneim AS, Eurich DT, Light PE, et al. Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer. Diabetes Obes Metab 2015;17:523-532
14. Burke MA, Mutharasan RK, Ardehali H. The sulfonylurea receptor, an atypical ATP-binding cassette protein, and its regulation of the KATP channel. Circ Res 2008;102:164-176
15. American Diabetes Association. Standards of Medical Care in Diabetesd2016. Diabetes Care 2016;39(Suppl. 1):S1-S112
16. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2015;58:429-442
17. Gunton JE, Cheung NW, Davis TM, Zoungas S, Colagiuri S; Australian Diabetes Society. A new blood glucose management algorithm for type 2 diabetes: a position statement of the Australian Diabetes Society. Med J Aust 2014;201:650-653
18. Zareba W, Cygankiewicz I. The QT interval. In Comprehensive Electrocardiology. 2nd ed. Macfarlane PW, van Oosterom A, Pahlm O, Kligfield P, Janse M, CammJ, Eds. London, Springer, 2011, p. 834-862
19. Chevalier P, Burri H, Adeleine P, et al.; Groupe d'Etude du Pronostic de l'Infarctus du Myocarde. QT dynamicity and sudden death aftermyocardial infarction: results of a long-term follow-up study. J Cardiovasc Electrophysiol 2003;14:227-233
20. Pathak A, Curnier D, Fourcade J, et al. QT dynamicity: a prognostic factor for sudden cardiac death in chronic heart failure. Eur J Heart Fail 2005;7:269-275
21. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007;50:1140-1147
22. Gill GV, Woodward A, Casson IF, Weston PJ. Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes-the 'dead in bed' syndrome revisited. Diabetologia 2009;52:42-45
23. Smetana P, Batchvarov V, Hnatkova K, Camm AJ, Malik M. Circadian rhythm of the corrected QT interval: impact of different heart rate correction models. Pacing Clin Electrophysiol 2003;26:383-386
24. Rautaharju PM, Surawicz B, Gettes LS, et al.; American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; American College of Cardiology Foundation; Heart Rhythm Society. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement fromthe American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society: endorsed by the International Society for Computerized Electrocardiology. Circulation 2009;119:e241-e250
25. International Diabetes Federation. IDF Diabetes Atlas. 7th Ed, 2015. Available from www.diabetesatlas.org. Accessed 21 March 2016
26. Schopman JE, Simon AC, Hoefnagel SJ, Hoekstra JB, Scholten RJ, Holleman F. The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and metaanalysis. Diabetes Metab Res Rev 2014;30:11-22
27. Beom JW, Kim JM, Chung EJ, et al. Corrected QT interval prolongation during severe hypoglycemia without hypokalemia in patients with type 2 diabetes. DiabetesMetab J 2013;37:190-195
28. Reno CM, Daphna-Iken D, Chen YS, Vander Weele J, Jethi K, Fisher SJ. Severe hypoglycemia-induced lethal cardiac arrhythmias are mediated by sympathoadrenal activation. Diabetes 2013;62:3570-3581
29. Riddle MC. Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation 2010;122:844-846
30. Extramiana F, Maison-Blanche P, Badilini F, Pinoteau J, Deseo T, Coumel P. Circadian modulation of QT rate dependence in healthy volunteers: gender and age differences. J Electrocardiol 1999;32:33-43
31. Banarer S, Cryer PE. Sleep-related hypoglycemiaassociated autonomic failure in type 1 diabetes: reduced awakening from sleep during hypoglycemia. Diabetes 2003;52:1195-1203
32. Jennum P, Stender-Petersen K, Rabøl R, Jørgensen NR, Chu PL, Madsbad S. The impact of nocturnal hypoglycemia on sleep in subjects with type 2 diabetes. Diabetes Care 2015;38:2151-2157
33. Ataklte F, Erqou S, Laukkanen J, Kaptoge S. Meta-analysis of ventricular premature complexes and their relation to cardiac mortality in general populations. Am J Cardiol 2013;112:1263-1270
34. Berry MG. Tobacco hypoglycemia. Ann Intern Med 1959;50:1149-1157
35. Hirai FE, Moss SE, Klein BE, Klein R. Severe hypoglycemia and smoking in a long-term type 1 diabetic population: Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care 2007;30:1437-1441
36. Bott S, Shafagoj YA, Sawicki PT, Heise T. Impact of smoking on the metabolic action of subcutaneous regular insulin in type 2 diabetic patients. Horm Metab Res 2005;37:445-449
37. Green JB, Bethel MA, Armstrong PW, et al.; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232-242
38. Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128
39. Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311-322
40. Marso SP, Bain SC, Consoli A, et al.; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834-1844